Royalty Pharma Financial Statements
NASDAQ: RPRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Royalty Pharma revenue and earnings
In fiscal 2025, Royalty Pharma generated $2.38 billion in revenue, up 5.1% from fiscal 2024. Net income was $770.9 million (-10.2% year over year), for a net margin of 32.4% versus a median of 37.9% in the prior 5 years. Operating margin was 65.6%.
Diluted earnings per share came in at $1.78, down from $1.91. Over the last 5 fiscal years, RPRX's revenue has grown at a 2.3% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Royalty Pharma income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2.38B | 2.26B | 2.35B | 2.24B | 2.29B | 2.12B | 1.81B | 1.79B |
| Revenue growth (YoY) | +5.06% | -3.86% | +5.24% | -2.28% | +7.87% | +16.98% | +1.08% | — |
| Research & Development | 452.00M | 2.00M | 52.00M | 177.11M | 200.08M | 26.29M | 83.04M | 392.61M |
| Operating Income | 1.56B | 1.29B | 1.49B | 307.06M | 1.43B | 1.60B | 2.62B | 1.36B |
| Interest Expense | 307.66M | 225.51M | 187.19M | 187.96M | 166.14M | 157.06M | 268.57M | 279.96M |
| Other Income (Expense) | -235.33M | 38.37M | 207.94M | -77.00M | -189.51M | 106.56M | -161.76M | 153.41M |
| Pretax Income | 1.32B | 1.33B | 1.70B | 230.06M | 1.24B | 1.70B | 2.46B | 1.52B |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | 770.95M | 858.98M | 1.13B | 42.83M | 619.73M | 975.04M | 2.35B | 1.38B |
| Net Income growth (YoY) | -10.25% | -24.31% | +2549.50% | -93.09% | -36.44% | -58.48% | +70.46% | — |
| EPS (Basic) | 1.79 | 1.92 | 2.54 | 0.10 | 1.49 | 1.32 | — | — |
| EPS (Diluted) | 1.78 | 1.91 | 2.53 | 0.10 | 1.49 | 1.32 | — | — |
| Shares Outstanding (Basic) | 429.80M | 448.19M | 447.60M | 437.96M | 414.79M | 375.44M | — | — |
| Shares Outstanding (Diluted) | 564.46M | 594.11M | 602.90M | 437.97M | 414.80M | 375.45M | — | — |
| EBITDA | 1.56B | 1.29B | 1.49B | — | — | — | — | — |
| Operating Margin | 65.58% | 57.10% | 63.37% | 13.73% | 62.49% | 75.17% | 144.59% | 76.02% |
| Net Margin | 32.42% | 37.95% | 48.20% | 1.91% | 27.07% | 45.94% | 129.45% | 76.76% |
This table shows 8 annual periods of Royalty Pharma's income statement, from FY 2025 back to FY 2018, across 15 line items including revenue, research & development, operating income. Values in USD; B = billions, M = millions. Fiscal periods follow RPRX's reporting calendar. What is a income statement?